Clinical spectrum of HTLV-I in south Florida. 1995

W J Harrington, and A Ucar, and P Gill, and S Snodgrass, and W Sheremata, and L Cabral, and M Rabin, and G E Byrne, and J Berger, and W Voight
Department of Medicine, FL 33136, USA.

A total of 113 patients with infection due to human T-cell leukemia virus type 1 (HTLV-I) were evaluated at the University of Miami from January 1988 to March 1993. Forty patients were identified with adult T-cell leukemia/lymphoma (ATLL) and 63 with HTLV-I-associated myelopathy (HAM). Three had concomitant ATLL and HAM. Two HAM patients co-infected with human immunodeficiency virus type 1 (HIV-I) developed clonal lymphoproliferative disease during the study period. Patients with ATLL have a poor prognosis; multiple chemotherapy regimens including high-dose cytotoxic agents have been utilized with a small impact on survival. Most of our patients are currently treated with experimental regimens. Rheumatologic or autoimmune illnesses were identified, mostly in HAM patients, and a small number developed immunodeficiencies in the absence of other definable etiologic factors. Most of the patients were immigrants from areas of endemicity in the Caribbean basin, although many Americans were also recognized. HTLV-I/II infection was diagnosed serologically and typed as HTLV-I by polymerase chain reaction (PCR) or a modified Western blot when a DNA sample was not available. In 24 of 40 patients with ATLL, Southern blot hybridization performed on DNA extracted from peripheral blood lymphocytes or tumor tissue demonstrated clonal HTLV-I integration. In South Florida, ATLL and HAM are now seen frequently. Since HTLV-I infection is associated with a 4% lifetime risk of developing ATLL and an additional 0.25% lifetime risk for developing HAM, a large pool of asymptomatically infected individuals must exist here.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D008232 Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified. Duncan's Syndrome,X-Linked Lymphoproliferative Syndrome,Duncan Disease,Epstein-Barr Virus Infection, Familial Fatal,Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males,Familial Fatal Epstein-Barr Infection,Immunodeficiency 5,Immunodeficiency, X-Linked Progressive Combined Variable,Lymphoproliferative Disease, X-Linked,Lymphoproliferative Syndrome, X-Linked, 1,Purtilo Syndrome,X-Linked Lymphoproliferative Disease,X-Linked Lymphoproliferative Disorder,Disease, Duncan,Disease, X-Linked Lymphoproliferative,Diseases, X-Linked Lymphoproliferative,Disorder, Lymphoproliferative,Disorder, X-Linked Lymphoproliferative,Disorders, Lymphoproliferative,Disorders, X-Linked Lymphoproliferative,Epstein Barr Virus Induced Lymphoproliferative Disease In Males,Epstein Barr Virus Infection, Familial Fatal,Familial Fatal Epstein Barr Infection,Immunodeficiency 5s,Immunodeficiency, X Linked Progressive Combined Variable,Lymphoproliferative Disease, X Linked,Lymphoproliferative Diseases, X-Linked,Lymphoproliferative Disorder,Lymphoproliferative Disorder, X-Linked,Lymphoproliferative Disorders, X-Linked,Lymphoproliferative Syndrome, X-Linked,Lymphoproliferative Syndromes, X-Linked,Purtilo Syndromes,Syndrome, Purtilo,Syndrome, X-Linked Lymphoproliferative,Syndromes, Purtilo,Syndromes, X-Linked Lymphoproliferative,X Linked Lymphoproliferative Disease,X Linked Lymphoproliferative Disorder,X Linked Lymphoproliferative Syndrome,X-Linked Lymphoproliferative Diseases,X-Linked Lymphoproliferative Disorders,X-Linked Lymphoproliferative Syndromes
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D005431 Florida State bounded on east by the Atlantic Ocean, on the south by the Gulf of Mexico, on the west by Alabama and on the north by Alabama and Georgia.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

W J Harrington, and A Ucar, and P Gill, and S Snodgrass, and W Sheremata, and L Cabral, and M Rabin, and G E Byrne, and J Berger, and W Voight
January 1991, Journal of acquired immune deficiency syndromes,
W J Harrington, and A Ucar, and P Gill, and S Snodgrass, and W Sheremata, and L Cabral, and M Rabin, and G E Byrne, and J Berger, and W Voight
August 1992, Revista medica de Chile,
W J Harrington, and A Ucar, and P Gill, and S Snodgrass, and W Sheremata, and L Cabral, and M Rabin, and G E Byrne, and J Berger, and W Voight
July 1980, American journal of ophthalmology,
W J Harrington, and A Ucar, and P Gill, and S Snodgrass, and W Sheremata, and L Cabral, and M Rabin, and G E Byrne, and J Berger, and W Voight
June 1994, Ophthalmology,
W J Harrington, and A Ucar, and P Gill, and S Snodgrass, and W Sheremata, and L Cabral, and M Rabin, and G E Byrne, and J Berger, and W Voight
June 1993, AIDS research and human retroviruses,
W J Harrington, and A Ucar, and P Gill, and S Snodgrass, and W Sheremata, and L Cabral, and M Rabin, and G E Byrne, and J Berger, and W Voight
January 1994, Molecular neurobiology,
W J Harrington, and A Ucar, and P Gill, and S Snodgrass, and W Sheremata, and L Cabral, and M Rabin, and G E Byrne, and J Berger, and W Voight
September 1985, Cancer research,
W J Harrington, and A Ucar, and P Gill, and S Snodgrass, and W Sheremata, and L Cabral, and M Rabin, and G E Byrne, and J Berger, and W Voight
May 1989, Lancet (London, England),
W J Harrington, and A Ucar, and P Gill, and S Snodgrass, and W Sheremata, and L Cabral, and M Rabin, and G E Byrne, and J Berger, and W Voight
June 1992, Uirusu,
W J Harrington, and A Ucar, and P Gill, and S Snodgrass, and W Sheremata, and L Cabral, and M Rabin, and G E Byrne, and J Berger, and W Voight
March 1992, Japanese journal of cancer research : Gann,
Copied contents to your clipboard!